View Author
patient cancer treatment study survival melanoma colorectal group colorectal cancer trial oxaliplatin interferon stage metastatic colorectal cancer analysis rt-pcr 5- fu /lv therapy month result temozolomide oncol rectal cancer hospital regimen irinotecan number dacarbazine rectal observation adjuvant capecitabine metastatic fluorouracil netherland disease perspective folfox chemotherapy blood sample cost-effectiveness metastasis-free survival ratio table article phase response erasmus mc colon randomisation tumour raltitrexed schedule event interferon group pegylated observation group surgery university hazard prognostic eortc signi analyses outcome recurrence-free survival melanoma cells bevacizumab review leucovorin adjuvant chemotherapy expert excision oncology value department lymph metastasi pharmacother
8 Most Recent Publications
|
Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in the Netherlands
(Article)
Mol, L. Koopman, M. Gils, C.W.M. van Ottevanger, P.B. Punt, C.J.A. |
2013-06-01
|
|
Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study)
(Article)
Busse, A. Rapion, J. Spatz, A. Eggermont, A.M.M. Keilholz, U. Fusi, A. Suciu, S. Nonnenmacher, A. Santinami, M. Kruit, W.H.J. Testori, A. Punt, C.J.A. Dalgleish, A.G. |
2013-04-29
|
|
Adjuvant chemotherapy in stage III colon cancer: Guideline implementation, patterns of use and outcomes in daily practice in the Netherlands
(Article)
Gils, C.W.M. van Koopman, M. Mol, L. Orlewska, E. Uyl-de Groot, C.A. Punt, C.J.A. |
2012-01-01
|
|
The CARTS study: Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery
(Article)
Bökkerink, G.M.J. Graaf, E.J.R. de Dwarkasing, R.S. Marijnen, C.A.M. Cats, A. Tollenaar, R.A.E.M. Hingh, I.H.J.T. de Rutten, H.J.T. Schelling, G.P. van der Tije, A.J. ten Leijtens, J.W.A. Lammering, G. Punt, C.J.A. Beets, G.L. Aufenacker, T.J. Pronk, A. Manusama, E.R. Hoff, C. Bremers, A.J.A. Verhoef, C. Wilt, J.H.W. de Nagtegaal, I.D. Rütten, H. Nuyttens, J.J.M.E. Meerten, E. van Doornebosch, P. Tanis, P.J. Derksen, E.J. |
2011-12-16
|
|
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)
(Article)
Patel, P. Suciu, S. Becker, J. Conry, R. Thompson, J.A. Hwu, W.-J. Agarwala, S.S. Engelen, K. Keilholz, U. Eggermont, A.M.M. Spatz, A. Mortier, L. Kruit, W.H.J. Robert, C. Schadendorf, D. Trefzer, U. Punt, C.J.A. Dummer, R. Davidson, N. |
2011-07-01
|
|
Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study)
(Article)
Fusi, A. Collette, S. Spatz, A. Eggermont, A.M.M. Keilholz, U. Busse, A. Suciu, S. Rietz, A. Santinami, M. Kruit, W.H.J. Testori, A. Punt, C.J.A. Dalgleish, A.G. |
2009-12-01
|
|
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
(Article)
Eggermont, A.M.M. Suciu, S. Kusic, Z. Dummer, R. Hauschild, A. Musat, E. Spatz, A. Keilholz, U. Santinami, M. Testori, A. Kruit, W.H.J. Marsden, J. Punt, C.J.A. Salès, F. Gore, M. MacKie, R.M. |
2008-07-14
|
|
A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer
(Article)
Krol, H.M. Koopman, M. Uyl-de Groot, C.A. Punt, C.J.A. |
2007-06-01
|
